Loading...
| Jan 01, 1970 | Daily Report |
| RISING BHARAT | News Count (102145) | |
23081. [Startup Bharat] How this Assam-based tea startup is rooting for sustainability with cotton teabags
Innovation and startups, ISRO/Defense/Water infrastructure/EV and other sectors
->
Startups in Bharat
English
Assam
Your Story
|
- Esah Tea from Mangaldoi, Assam, which has developed pyramid organic cotton teabags, promises your cup of tea in either of its 60 plus tea variants.
- According to a report by Eon Market Research (EMR), India consumed around 1.10 million tons of tea in 2019. The tea market is expected to grow at a CAGR of 4.2 percent and 1.40 million tons of tea is expected to be consumed by 2025.
- One such startup is Esah Tea, started by a 26-year-old teapreneur, Bijit Sarma, hailing from Mangaldoi, Assam. Esah Tea offers a range of single-origin organic tea blends that are carefully curated from 150+ local gardens and marginal tea growers.
23082. This cycle startup is pushing the pedal on innovation to crack India’s growing market
Innovation and startups, ISRO/Defense/Water infrastructure/EV and other sectors
->
Startups in Bharat
English
Maharashtra
Your Story
|
- Backed by A91 Partners, Mumbai-based cycle startup Ninety One claims to sell over 20,000 bicycles every month. The startup aims to ramp up manufacturing facilities and focus on brand building after a recent fundraise.
- Alpha Vector’s first product viper was released in 2017. As of now, the company’s bikes are available across their own website, online marketplaces and multi-brand outlets.
- Started as a bootstrapped firm, Alpha Vector set up a manufacturing unit in Ahmedabad, Gujarat, in 2021, where the firm produces about 12,000 cycles every month. An additional 15,000 bikes’ production is outsourced to another manufacturer.
23083. ब्लैक फंगस के खिलाफ स्वदेशी दवा उतारने का ऐलान, जानें दवाई से जुड़ी अहम घोषणा Key points:
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
Dainik Jagran
|
- केंद्र देश में ब्लैक फंगस यानी म्यूकोरमायकोसिस के ब़़ढते मामलों के बीच एक घरेलू कंपनी ने इसकी नई दवा उतारने का एलान किया है। हैदराबाद स्थित एमएसएन लैब्रोरेटरीज ने भारतीय बाजार में पोसाकोनाजोल लांच करने की घोषणा की है।
- इस दवा को कंपनी ने 100एमजी डिलेड रिलीज टैबलेट और 300 एमजी इंजेक्शन के रूप में पेश करने की घोषषणा की है। कोविड-19 से ठीक हो रहे कई मरीजों में म्यूकोरमायकोसिस नामक दुर्लभ और मारक फंगल संक्रमण पाया गया है, जो ब्लैक फंगस के नाम से मशहूर है।
- कंपनी का दावा है कि उसकी इस दवा को भारतीय औषषधि महानियंत्रक ([डीसीजीआइ)] से मंजूरी मिल चुकी है।
23084. COVID-19: MSN Laboratories initiates Phase III clinical trial of Molnupiravir
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
ANI
|
- After the launch of Posaone (Posaconazole) tablet used in the treatment of black fungus, MSN on Wednesday announced that it received a clearance from the Drug Controller General of India (DGCI) last week to conduct a third phase of clinical trial on mild to moderate COVID-19 patients.
- Set up in Hyderabad, MSN will start its clinical trials in more than 40 sites across India and the first dosing is expected to begin soon. The clinical trials will be performed on more than 2,400 subjects suffering from mild to moderate COVID-19, the company said in a statement.
- Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for COVID treatment. MSN research and development team has developed both the API and formulation, is expecting to launch soon after its successful conclusion of clinical study followed by regulatory approval, it added.
23085. DRDO की बनी स्वदेशी कोरोना दवा 2DG अब बाजार में मिलेगी, डॉ रेड्डीज लैबोरेट्रीज ने बताई कीमत
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
Hindi
India
One India Hindi
|
- हैदराबाद स्थित डॉ. रेड्डी लैबोरेट्रीज ने डीआरडीओ की बनाई एंटी कोविड-19 दवा 2डीजी की कीमत और नाम तय कर दिए हैं। बाजार में कोरोना की स्वदेशी दवा 2DG अब 2DGTM के नाम से बिकेगी। इसके एक सैशे की कीमत 990 रुपये तय की गई है।
- डीआरडीओ ने कहा था कि आमतौर पर 2DG कोरोना दवा को डॉक्टरों द्वारा मध्यम से गंभीर कोविड रोगियों को दिया जाता है। ये 10 दिनों का कोर्स होता है।
- एंटी कोविड-19 ड्रग 2डीजी जो अब बाजार में 2DGTM के नाम से मिलने वाली है, इस दवा को डीआरडीओ के इंस्टीट्यूट ऑफ न्यूक्लियर मेडिसिन एंड अलायड साइंसेस (आईएनएमएएस) ने हैदराबाद सेंटर फॉर सेल्युलर एंड मॉलिक्युलर बायोलॉजी (सीसीएमबी) के साथ मिलकर बनाया है। इस दवा को 2-deoxy-D-glucose नाम दिया गया है। इस दवा को बनाने की जिम्मेदारी डॉ. रेड्डी लैबोरेट्रीज ने ली है।
23086. India's first mRNA Covid-19 vaccine moves to advanced clinical trials
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
The Tribune
|
- India's first mRNA covid-19 vaccine moves to advanced clinical trials mRNA based vaccines got global focus following the huge success of Pfizer BioTech and Fosum pharma's covid-19 vaccine comirnaty and U.S. based Moderna's covid-19 vaccine mRNA -1273
- Subsidiary Gennova Biopharmaceuticals, entering into the next stage of clinical trials. A few days ago, India had approved the world's first plasmid DNA vaccine, ZyCOV-D from Zydus cadila.
- mRNA vaccines present various benefits as they are non infectious, non integrating in nature, and degraded by normal cellular mechanisms . At present, globally, other companies are also developing mRNA- based covid-19 vaccines. Gennova mRNA based covid-19 vaccine developement program was partly funded by the department of Biotechnology (DBT). Govt. of India under Ind-CEPI, way back in June 2020. Mission covid-19 .suraksha- The Indian covid-19 vaccine Developement Mission, implemented by BIRAC.
23087. India’s Indigenously Developed DNA-Based Vaccine Hailed as Potential Game-Changer in COVID-19 Fight
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
The Weather Channal
|
- India Indigenously Developed DNA- based vaccine hailed as potential game changer in covid-19 fight. DNA- based covid-19 vaccine to be administered in adults and children 12 years and above.
- Zydus group's vaccine Technology Centre (VTC) and translational Health Science and Technology (THSTI) , an autonomous institute of the department of the department of Biotechnology, played a vital role in this success story.
- DNA vaccination marks a radically new approach. it involves the direct introduction into appropriates tissues of a plasmid containing the DNA sequence encoding the antigen (&) against which an immune response is sought and relies on in site production of the target antigen
23088. 1.50% Adults In India Have Got At Least One Vaccine Dose
India Fights Corona: Vaccination Drive and Initiatives
English
India
The Times Of India
|
- Reliance Life Sciences, is expected to start phase I clinical studies of its indigenous Covid-19 vaccine soon.
- The vaccine under developement is a protien based covid-19 vaccine and is expected to be launched by the first quarter 2022.
- MTM inactivates the virus within the sample and stabilizes the RNA, to make collection, transportation and processing safer.
23089. Joint COVAX Statement on Supply Forecast for 2021 and early 2022
Indian Diplomacy
->
Economic and Medical Support to Other Countries
English
India
WHO
|
- Twelve months ago, the world came together to support COVAX, a multilateral initiative aimed at guaranteeing global access to life-saving COVID-19 vaccines. COVAX immediately began securing financing, entering into negotiations with vaccine developers and manufacturers and addressing the host of technical and operational challenges associated with rolling out the largest and most complex vaccination programme in history.
- COVAX expects to have access to 1.425 billion doses of vaccine in 2021, in the most likely scenario and in the absence of urgent action by producers and high-coverage countries to prioritize COVAX. These doses, approximately 1.2 billion will be available for the lower income economies participating in the COVAX Advance Market Commitment (AMC)
- The Access to COVID-19 Tools ACT-Accelerator, is a new, ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. It was set up in response to a call from G20 leaders in March and launched by the WHO, European Commission, France and The Bill & Melinda Gates Foundation in April 2020
23090. India has administered over 86 crore total doses of the Covid-19 vaccine.
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
Business Line
|
- Uttar pradesh cesh tops the list in terms of the highest number of first doses administered, followed by Maharashtra and Madhya Pradesh.
- The monthly expansion in services and manufacturing activity coincided with relatively low new Covid-19 cases and a pick-up in the pace of vaccinations — more than 834 million doses have been administered so far in the nation of 1.3 billion people.
- India’s economy showed signs it’s ready to accelerate, thanks to its services sector resuming expansion and manufacturing activity retaining growth momentum in August, says a report. The story behind the vaccine development and dose of innovation the Ellas have brought to India’s biotech industry